Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for HIV-1 uninfected partner:~* Partner within an HIV-1 discordant heterosexual relationship~* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant~* Plan to remain in the relationship for the duration of the study period~* Adequate renal, hepatic \& hematologic function~* Negative Hepatitis B surface antigen test~* Willing and able to provide written informed consent \& locator information~Exclusion Criteria for HIV-1 uninfected partner:~* Current pregnancy, or planning to become pregnant during the study period~* Currently breastfeeding~* Concurrent enrollment in another HIV-1 vaccine or prevention trial~* Receiving ongoing antiretroviral therapy~* Repeated positive urine dipstick tests for glycosuria or proteinuria~* Active and serious infections~* History of pathological bone fractures not related to trauma~Inclusion Criteria for HIV-1 infected partner:~* Partner within an HIV-1 discordant heterosexual relationship~* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant~* HIV-1 infected based on positive EIA~* No history of any clinical AIDS-defining diagnoses~* Plan to remain in the relationship for the duration of the study period~* Willing and able to provide written informed consent \& locator information~Exclusion Criteria for HIV-1 infected partner:~* Current use of antiretroviral therapy~* Concurrent enrollment in another HIV-1 treatment trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tenofovir Disoproxil Fumarate (TDF) (Type: ACTIVE_COMPARATOR): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
- Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Type: ACTIVE_COMPARATOR): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo TDF + Placebo FTC/TDF orally, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).